Page last updated: 2024-10-19

inositol and Chronic Hepatitis C

inositol has been researched along with Chronic Hepatitis C in 2 studies

Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Forton, DM1
Hamilton, G1
Allsop, JM1
Grover, VP1
Wesnes, K1
O'Sullivan, C1
Thomas, HC1
Taylor-Robinson, SD1
Byrnes, V1
Miller, A1
Lowry, D1
Hill, E1
Weinstein, C1
Alsop, D1
Lenkinski, R1
Afdhal, NH1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection Before and After Pegylated Interferon Alfa-2a and Ribavirin Therapy[NCT00788918]100 participants (Actual)Interventional2008-11-30Completed
Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.[NCT02745132]Phase 480 participants (Anticipated)Interventional2016-06-30Not yet recruiting
A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects[NCT00136214]22 participants (Actual)Observational2004-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Neurocognitive Tests for Cerebral Function

A battery of pen and paper neurocognitive tests where subject means are reported compared to the normative Z score. Data is reported at baseline (T1), week 12 on treatment (T2) and 12 weeks after treatment (week 60, T3). Improvements are increases in the test result compared to baseline as determined against the Z score. tests performed included Hopkins learning trials (HVLT), a measure of of verbal learning and memory and the Roy-Osterrieth Complex figure test (ROCF) which evaluates visio-spatal abilities, memory, planning and working memory. Improvements in the score (increases in value compared, either less negative or more positive to the Z score) shown in the table are reflective of improvements in these neurocognitive parameters. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline and only done in treated group and not controls

,
InterventionZ-score (Mean)
HVLT, Verbal Learning Total, T1HVLT, Verbal Learning Total, T2HVLT, Verbal Learning Total, T3ROCF, T1ROCF, T2ROCF,T3
Interferon Treated Group-1.43-0.78-0.70.340.150.33
Non-treated Cohort Control-2.0-1.16NA-1.00.05NA

Ratios of Cerebral Metabolites Choline (CH), Myoinisitol (MI) and N-acety Aspartate (NAA)to Creatine (Cr) in 3 Brain Regions Including Basal Ganglia, Frontal Cortex and Left Dorsolateral Prefrontal Cortex

Evaluation of changes in MR spectroscopy. reductions in ratio of Cho and MI reflect improvements in cerebral inflammation and improvement in cognition. Increases in the NAA ratio are suggestive of improvement in cognitive function. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline

,
Interventionratio (Mean)
Basal Ganglia, T1, Cho/CrBasal Ganglia,T2, Cho/CrBasal Ganglia, T3, Cho/CrBasal Ganglia, T1, MI/CrBasal Ganglia T2. MI/CBasal Ganglia T3, MI/CFrontal Cortex T1, Cho/CrFrontal Cortex T2, Cho/CrFrontal Cortex T3, Cho/CrBasal Ganglia T1, NAA/CrBasal Ganglia T2, NAA/CrBasal Ganglia T3, NAA/CrFrontal Cortex T1,Mi/CrFrontal Cortex T2, MI/CrFrontal Cortex T3, MI/CrFrontal Cortex T1, NAA/CrFrontal Cortex T2, NAA/CrFrontal Cortex T3, NAA/CrDLPFC T1, Cho/CrDLPFC T2, Cho/CrDLPFC T3, Cho/CrDLPFC T1, MI/CrDLPFC T2, MI/CrDLPFC T3/ MI/CrDLPFC T1, NAA/CrDLPFC T2, NAA/CrDLFPC T3, NAA/Cr
Interferon Treated Group0.420.280.340.780.710.750.290.260.291.261.251.090.680.750.711.731.741.750.310.250.260.790.750.931.721.651.78
Non-treated Cohort Control0.300.28NA0.780.72NA0.280.29NA1.281.07NA0.771.19NA1.551.72NA0.270.27NA0.780.86NA1.611.60NA

Trials

1 trial available for inositol and Chronic Hepatitis C

ArticleYear
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders

2012
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders

2012
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders

2012
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders

2012

Other Studies

1 other study available for inositol and Chronic Hepatitis C

ArticleYear
Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study.
    Journal of hepatology, 2008, Volume: 49, Issue:3

    Topics: Adult; Attention; Brain; Case-Control Studies; Cognition; Creatine; Female; Hepatitis C, Chronic; Hu

2008